{
    "nct_id": "NCT02775695",
    "official_title": "Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer",
    "inclusion_criteria": "* Histologically or cytologically confirmed pancreatic adenocarcinoma which may be acquired using a fine needle aspiration.\n* Not received any prior therapy.\n* Established resectable pancreatic cancer based on radiographic imaging.\n* Patients who will receive neoadjuvant therapy (chemoradiation) are eligible.\n* Age ≥18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%).\n* Have no active or chronic infection with HIV, Hepatitis B or Hepatitis C\n* Life expectancy of greater than six months.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Normal organ and marrow function as defined below:\n\n  1. leukocytes ≥3,000/microliter (mcL)\n  2. absolute neutrophil count ≥1,500/mcL\n  3. platelets ≥100,000/mcL\n  4. total bilirubin < 2 mg/dL or has demonstrated progressive decline within two weeks of biliary decompression to allow for appropriate gemcitabine dose modification.\n  5. Aspartate Aminotransferase (AST)[Serum Glutamic Oxaloacetic Transaminase (SGOT] )/ Alanine Aminotransferase (ALT) [Serum Glutamic Pyruvic Transaminase(SGPT)] ≤3 × institutional upper limit of normal\n  6. Creatinine clearance ≥60 mL/min/1.73 m^2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with more clinically advanced pancreatic cancer (borderline resectable, locally advanced, or metastatic).\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because the effects of metakaryocidal agents have the potential for teratogenic or abortifacient effects.\n* Previous history of other malignancy (other than cured basal or squamous cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within two years of study enrollment.\n* Active or chronic HIV, hepatitis B or hepatitis C.\n* Patients who are receiving other investigational drugs or enrolled in other clinical trials.\n* Inability to undergo scheduled blood acquisition per protocol.\n* Drug specific exclusion including history of allergic reactions to tetracyclines.\n* Prior treatment with doxycycline within a seven day washout period prior to initiating treatment with alternate antimetakaryocidal medication.",
    "miscellaneous_criteria": ""
}